To additionally complicate clinical decision making, two recent molecular landscape studies demonstrated the existence of different molecular GC subtypes.7,8 The Asian Cancer Research Group (ACRG) categories were determined on the basis of gene expression profiling of tumors with microsatellite instability (MSI), tumors with an epithelial-to-mesenchymal transition phenotype, tumors with a p53 signature (CDKN1A and MDM2 expressing), or tumors without the p53 signature. Here, TP53 is linked to cancer.